Cognition Therapeutics, Inc.

Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company leveraging two decades of mechanistic, translational, and clinical research to deliver effective treatments for neurodegenerative diseases affecting millions of families. We are building on breakthroughs in well-established biological pathways underlying neurodegeneration, to lead the charge in developing accessible, novel small-molecule therapies for age-related degenerative diseases that have historically been understudied, underserved, and misunderstood. Zervimesine (CT1812) is Cognition Therapeutics’ investigational first-in-class oral therapy. The goal of treatment is to protect brain synapses before irreversible neuronal decline occurs, which may offer an accessible solution for people with neurodegenerative diseases, such as dementia with Lewy bodies (DLB) and Alzheimer’s disease. Led by a dedicated and nimble team headquartered in Purchase, NY, our work is driven by a deep commitment to supporting patients and caregivers impacted by these challenging diseases.